Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

FOUND: 5 | Mind Blowing Facts

Drugmaker Gilead to help fund monkeypox education for LGBTQ+ groups

Drugmaker Gilead Sciences plans to announce on Tuesday that it will provide up to $5 million in grants to help a coalition of LGBTQ+ and human rights advocacy groups craft public health responses to monkeypox outbreaks, the company said.

Reuters

Direct-acting antivirals can cure hepatitis C and prisons are now leading efforts to eliminate the virus

While most medical attention has been on COVID, work has been underway to eliminate another viral disease, hepatitis C.

The Conversation

Recap Of Friday's Biotech Catalysts - End Of The Day Summary

Bristol Myers Squibb (NYSE:BMY) received European Medicines Agency (EMA) Positive CHMP Opinion recommending approval for Opdualag (nivolumab and relatlimab) for treatment of patients with Unresectable or Metastatic Melanoma based on results from the Phase 2/3 RELATIVITY-047 trial. Bristol Myers shares traded in a range of $72.48 to $73.61 on a…

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Gilead Sciences Whale Trades For July 14

Someone with a lot of money to spend has taken a bearish stance on Gilead Sciences (NASDAQ:GILD). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Gilead Again Seeks HIV Drug Approval From FDA After Addressing Vial Compatibility Issues

Gilead Sciences (NASDAQ: GILD) resubmitted the New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lenacapavir, an investigational, long-acting HIV-1 capsid inhibitor, for the treatment of HIV-1 infection.

Benzinga

Traders See Bumpy Road Ahead For Gilead Sciences

Gilead Sciences, Inc. (NASDAQ: GILD) climbed on Wednesday, even as the S&P 500 ended the day with losses.

Benzinga

Why Gilead Is Cheapest Large-Cap Biotech Despite Some Not So Favorable Acquisitions

Even after spending over $40 billion in the past five years on acquisitions, none of the deals for Gilead Sciences Inc (NASDAQ: GILD) has delivered the blockbuster in cancer as it looked to venture away from the HIV franchise.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Here's How Much $100 Invested In Gilead Sciences 15 Years Ago Would Be Worth Today

Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 15 years by 1.22% on an annualized basis producing an average annual return of 7.45%. Currently, Gilead Sciences has a market capitalization of $74.42 billion.

Benzinga

$1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much

Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 7.56% on an annualized basis producing an average annual return of 14.71%. Currently, Gilead Sciences has a market capitalization of $75.20 billion.

Benzinga

Where Gilead Sciences Stands With Analysts

Over the past 3 months, 11 analysts have published their opinion on Gilead Sciences (NASDAQ:GILD) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga

Gilead Sciences Q1 Results Surpass Street Expectation, FY22 Outlook Midpoint Trails Consensus

Gilead Sciences, Inc. (NASDAQ: GILD) reported firs

Benzinga

Recap: Gilead Sciences Q1 Earnings

Gilead Sciences (NASDAQ:GILD) reported its Q1 earnings results on Thursday, April 28, 2022 at 04:01 PM. Here's what investors need to know about the announcement.

Benzinga

Gilead Sciences's Earnings Outlook

Gilead Sciences (NASDAQ:GILD) is set to give its latest quarterly earnings report on Thursday, 2022-04-28. Here's what investors need to know before the announcement. Analysts estimate that Gilead Sciences will report an earnings per share (EPS) of $1.80.

Benzinga

1st COVID treatment for kids under 12 gets FDA approval. What to know about Veklury

The Food and Drug Administration approved Veklury — also known as the drug remdesivir — as the first COVID-19 treatment for children younger than 12 on Monday, April 25.

McClatchy Washington Bureau

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

If You Invested $1000 In Gilead Sciences 20 Years Ago, Here's How Much You Would Have Today

Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 7.99% on an annualized basis producing an average annual return of 15.38%. Currently, Gilead Sciences has a market capitalization of $79.98 billion.

Benzinga

Where Gilead Sciences Stands With Analysts

Within the last quarter, Gilead Sciences (NASDAQ:GILD) has observed the following analyst ratings:

Benzinga

Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years

Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 6.62% on an annualized basis producing an average annual return of 13.94%. Currently, Gilead Sciences has a market capitalization of $75.77 billion.

Benzinga

10 Biggest Price Target Changes For Monday

Wells Fargo cut the price target on Gilead Sciences, Inc. (NASDAQ: GILD) from $70 to $63. Gilead Sciences shares rose 0.4% to $59.91 in pre-market trading.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years

Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 6.58% on an annualized basis.

Benzinga

Where Gilead Sciences Stands With Analysts

Within the last quarter, Gilead Sciences (NASDAQ:GILD) has observed the following analyst ratings:

Benzinga

If You Invested $100 In This Stock 20 Years Ago, Here's How Much You Would Have Today

Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 7.4% on an annualized basis.

Benzinga

Gilead Sciences: Q4 Earnings Insights

Gilead Sciences (NASDAQ:GILD) reported its Q4 earnings results on Tuesday, February 1, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Benzinga

Earnings Outlook For Gilead Sciences

Gilead Sciences (NASDAQ:GILD) is set to give its latest quarterly earnings report on Tuesday, 2022-02-01. Here's what investors need to know before the announcement. Analysts estimate that Gilead Sciences will likely report an Earnings Per Share (EPS) of $1.58.

Benzinga

What 5 Analyst Ratings Have To Say About Gilead Sciences

Within the last quarter, Gilead Sciences (NASDAQ:GILD) has observed the following analyst ratings:

1 2 3 4 5

People

Tony Zhang

14 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

European Medicines Agency

Rhythm Pharmaceuticals

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.